Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

VERTEX PHARMACEUTICALS INC / MA Director's Dealing 2017

Jun 5, 2017

29864_dirs_2017-06-05_b0fe36c8-bf5d-426b-804a-89e7cd08a880.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2017-06-01

Reporting Person: YOUNG WILLIAM D (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2017-06-01 Common Stock A 2188 $0.00 Acquired 5129 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2017-06-01 Stock Option (Right to Buy) $125.71 M 5295 Acquired 2027-05-31 Common Stock (5295) Direct

Footnotes

F1: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date.

F2: Fully vested.